共 50 条
Presenilin-dependent γ-secretase-mediated control of p53-associated cell death in Alzheimer's disease
被引:151
|作者:
da Costa, CA
Sunyach, C
Pardossi-Piquard, R
Sévalle, J
Vincent, B
Boyer, N
Kawarai, T
Girardot, N
George-Hyslop, PS
Checler, F
机构:
[1] Univ Nicaragua, Inst Mol & Cellular Pharmacol, Coeduc Unit Res 6097, Team Fdn Med Res,Natl Ctr Sci Res,Natl Union Auto, F-06560 Valbonne, France
[2] Univ Toronto, Dept Med, Ctr Res Neurodegenerat Dis, Toronto, ON, Canada
[3] Univ Hlth Network, Toronto, ON, Canada
[4] Grp Hosp Pitie Salpetriere, Med Res Unit 289, F-75634 Paris, France
[5] Grp Hosp Pitie Salpetriere, Natl Inst Hlth, F-75634 Paris, France
关键词:
presenilins;
gamma-secretase;
AICD;
apoptosis;
p53;
Alzheimer's disease;
D O I:
10.1523/JNEUROSCI.0651-06.2006
中图分类号:
Q189 [神经科学];
学科分类号:
071006 ;
摘要:
Presenilins ( PSs) are part of the gamma-secretase complex that produces the amyloid beta-peptide ( A beta) from its precursor [ beta-amyloid precursor protein ( beta APP)]. Mutations in PS that cause familial Alzheimer's disease ( FAD) increase A beta production and trigger p53-dependent cell death. We demonstrate that PS deficiency, catalytically inactive PS mutants, gamma-secretase inhibitors, and beta APP or amyloid precursor protein-like protein 2 ( APLP2) depletion all reduce the expression and activity of p53 and lower the transactivation of its promoter and mRNA expression. p53 expression also is diminished in the brains of PS- or beta APP-deficient mice. The gamma- and epsilon-secretase-derived amyloid intracellular C-terminal domain ( AICD) fragments ( AICDC59 and AICDC50, respectively) of beta APP trigger p53-dependent cell death and increase p53 activity and mRNA. Finally, PS1 mutations enhance p53 activity in human embryonic kidney 293 cells and p53 expression in FAD-affected brains. Thus our study shows that AICDs control p53 at a transcriptional level, in vitro and in vivo, and that FAD mutations increase p53 expression and activity in cells and human brains.
引用
收藏
页码:6377 / 6385
页数:9
相关论文